Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

250
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
250
Human Genetics01:28

Human Genetics

793
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
793
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

350
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
350
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

510
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
510
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

252
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
252
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

335
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
335

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older-Age Bipolar Disorder ISBD Task Forces.

Bipolar disorders·2026
Same author

Interpersonal stress, epigenetic indices of inflammation, and depressive symptoms: Longitudinal associations from adolescence to young adulthood.

Neurobiology of stress·2026
Same author

Developmental Trauma as a Prognostic Factor for Later Psychotic Disorder in an Adolescent Clinical Cohort: A 20-Year Follow Up Study.

Acta psychiatrica Scandinavica·2026
Same author

Impact of sex differences on the association between clinical predictors and electroconvulsive therapy outcomes: results from the Dutch ECT Consortium (DEC).

Journal of affective disorders·2026
Same author

Decomposing neuroanatomical heterogeneity in depression: insights from an ENIGMA major depressive disorder working group study in 5146 individuals.

Translational psychiatry·2026
Same author

Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.

Nature genetics·2026
Same journal

Neuroimaging of Heterogeneity in Neuropsychiatric Disorders: Toward Disease Progression Modeling.

Biological psychiatry·2026
Same journal

Impact of Transcranial Direct Current Stimulation-Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial.

Biological psychiatry·2026
Same journal

Remembering Jon-Kar Zubieta, M.D., Ph.D.

Biological psychiatry·2026
Same journal

Kappa opioid receptor availability in borderline personality disorder: An in-vivo investigation with [<sup>11</sup>C]EKAP PET imaging.

Biological psychiatry·2026
Same journal

From Satiety to Substance Use: Neural Mechanisms of GLP-1 Signaling in Appetite and Reward.

Biological psychiatry·2026
Same journal

Distinct and Shared Molecular Mechanisms Underlie Morphological-Functional Overcoupling and Undercoupling in Major Depressive Disorder.

Biological psychiatry·2026
See all related articles

Related Experiment Video

Updated: Oct 8, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.3K

Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness.

Jurjen J Luykx1, Dore Loef2, Bochao Lin3

  • 1Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands; Outpatient second opinion clinic, GGNet Mental Health, Warnsveld, the Netherlands.

Biological Psychiatry
|December 27, 2021
PubMed
Summary
This summary is machine-generated.

Polygenic risk scores for schizophrenia (PRS-SCZ) predict electroconvulsive therapy (ECT) effectiveness in major depressive episodes. Higher PRS-SCZ was linked to greater symptom reduction and remission rates in ECT patients.

Keywords:
DepressionElectroconvulsive therapy (ECT)Polygenic liabilitiesSchizophrenia

More Related Videos

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.6K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

596

Related Experiment Videos

Last Updated: Oct 8, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.3K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.6K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

596

Area of Science:

  • Psychiatry
  • Genetics
  • Clinical Neuroscience

Background:

  • Electroconvulsive therapy (ECT) is highly effective for severe major depressive episodes (MDEs).
  • Established biological predictors of ECT outcomes are lacking.
  • Polygenic risk scores (PRSs) show potential for treatment response prediction in psychiatry.

Purpose of the Study:

  • To investigate the association between PRSs for major depressive disorder, schizophrenia (SCZ), cross-disorder, and antidepressant response with ECT effectiveness.
  • To determine if PRS-SCZ can predict treatment outcomes in patients with MDE undergoing ECT.

Main Methods:

  • A cohort of 288 patients with MDE across 3 countries was analyzed.
  • The primary outcome was the change in Hamilton Depression Rating Scale (HDRS) scores post-ECT.
  • Regression analyses were performed using PRSs as predictors, controlling for covariates.

Main Results:

  • The PRS for schizophrenia (PRS-SCZ) was significantly associated with a greater decrease in HDRS scores (R 2 = 6.94%, p < .0001).
  • PRS-SCZ also predicted higher remission rates (R 2 = 4.63%, p = .0018) and results were consistent across countries.
  • Other PRSs did not show significant associations with ECT outcomes at the Bonferroni-corrected threshold.

Conclusions:

  • A linear association exists between PRS-SCZ and ECT outcomes in MDE patients.
  • PRS-SCZ shows relevance for predicting treatment response in psychiatric conditions.
  • While not yet for clinical decision-making, PRS-SCZ warrants further investigation for ECT treatment optimization.